Last reviewed · How we verify

NeuroDerm Ltd. — Portfolio Competitive Intelligence Brief

NeuroDerm Ltd. pipeline: 1 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 3 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Levodopa and carbidopa Levodopa and carbidopa marketed Dopamine precursor with peripheral decarboxylase inhibitor Dopamine pathway; aromatic L-amino acid decarboxylase (inhibited by carbidopa) Neurology
Placebo for Oral IR-LD/CD Placebo for Oral IR-LD/CD phase 3
ND0612 ND0612 phase 3 Dopamine precursor (levodopa) combination therapy Dopamine pathway; levodopa is converted to dopamine via aromatic amino acid decarboxylase Neurology
Oral IR-LD/CD Oral IR-LD/CD phase 3 Dopamine replacement therapy Dopamine pathway; aromatic amino acid decarboxylase inhibition Neurology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AbbVie · 1 shared drug class
  2. Baylor College of Medicine · 1 shared drug class
  3. Bial - Portela C S.A. · 1 shared drug class
  4. IRCCS San Raffaele Roma · 1 shared drug class
  5. Intec Pharma Ltd. · 1 shared drug class
  6. Pfizer · 1 shared drug class
  7. Ross D. Zafonte, MD · 1 shared drug class
  8. University of Buenos Aires · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for NeuroDerm Ltd.:

Cite this brief

Drug Landscape (2026). NeuroDerm Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/neuroderm-ltd. Accessed 2026-06-10.

Related